Merck & Company Inc (MRK) - Total Liabilities
Based on the latest financial reports, Merck & Company Inc (MRK) has total liabilities worth $-51.91 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Merck & Company Inc (MRK) cash flow conversion to assess how effectively this company generates cash.
Merck & Company Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Merck & Company Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Merck & Company Inc to evaluate the company's liquid asset resilience ratio.
Merck & Company Inc Competitors by Total Liabilities
The table below lists competitors of Merck & Company Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Novartis AG
MX:NVSN
|
Mexico | MX$64.40 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $69.02 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
China | CN¥603.80 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF62.82 Billion |
|
HSBC Holdings plc
MX:HBCN
|
Mexico | MX$3.04 Trillion |
|
Morgan Stanley
NYSE:MS
|
USA | $1.25 Trillion |
|
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
|
France | €74.70 Billion |
|
Philip Morris International Inc
NYSE:PM
|
USA | $77.21 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Merck & Company Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Merck & Company Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merck & Company Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merck & Company Inc (1985–2025)
The table below shows the annual total liabilities of Merck & Company Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $-51.91 Billion | -173.38% |
| 2024-12-31 | $70.73 Billion | +2.45% |
| 2023-12-31 | $69.04 Billion | +9.41% |
| 2022-12-31 | $63.10 Billion | -6.43% |
| 2021-12-31 | $67.44 Billion | +1.89% |
| 2020-12-31 | $66.18 Billion | +13.34% |
| 2019-12-31 | $58.40 Billion | +4.74% |
| 2018-12-31 | $55.76 Billion | +4.60% |
| 2017-12-31 | $53.30 Billion | -3.21% |
| 2016-12-31 | $55.07 Billion | -3.23% |
| 2015-12-31 | $56.91 Billion | +15.26% |
| 2014-12-31 | $49.38 Billion | -7.40% |
| 2013-12-31 | $53.32 Billion | +5.23% |
| 2012-12-31 | $50.67 Billion | +5.16% |
| 2011-12-31 | $48.19 Billion | -1.62% |
| 2010-12-31 | $48.98 Billion | -3.65% |
| 2009-12-31 | $50.83 Billion | +95.28% |
| 2008-12-31 | $26.03 Billion | -6.23% |
| 2007-12-31 | $27.76 Billion | +12.82% |
| 2006-12-31 | $24.60 Billion | +0.59% |
| 2005-12-31 | $24.46 Billion | +6.92% |
| 2004-12-31 | $22.88 Billion | +8.45% |
| 2003-12-31 | $21.10 Billion | -13.66% |
| 2002-12-31 | $24.43 Billion | +5.61% |
| 2001-12-31 | $23.13 Billion | +15.34% |
| 2000-12-31 | $20.06 Billion | +5.94% |
| 1999-12-31 | $18.93 Billion | +23.37% |
| 1998-12-31 | $15.35 Billion | +28.15% |
| 1997-12-31 | $11.98 Billion | +19.60% |
| 1996-12-31 | $10.01 Billion | +2.07% |
| 1995-12-31 | $9.81 Billion | +3.17% |
| 1994-12-31 | $9.51 Billion | +8.53% |
| 1993-12-31 | $8.76 Billion | +60.58% |
| 1992-12-31 | $5.46 Billion | +36.82% |
| 1991-12-31 | $3.99 Billion | +9.37% |
| 1990-12-31 | $3.65 Billion | +33.74% |
| 1989-12-31 | $2.73 Billion | -16.67% |
| 1988-12-31 | $3.27 Billion | -8.18% |
| 1987-12-31 | $3.56 Billion | +40.50% |
| 1986-12-31 | $2.54 Billion | +11.81% |
| 1985-12-31 | $2.27 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also pr… Read more